Hepatocyte growth factor in physiology and infectious diseases

Cytokine

Volumn 98, Issue , 2017, Pages 97-106

  Imamura, Ryu ^a   Matsumoto, Kunio ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Hepatocyte growth factor; HGF; Infectious diseases; Met; Regeneration

Indexed keywords

PROTEIN TYROSINE KINASE; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; HGF PROTEIN, HUMAN; MET PROTEIN, HUMAN;

ALPHA CHAIN; ANTIINFLAMMATORY ACTIVITY; BACTERIAL KERATITIS; BETA CHAIN; CANCER CELL; CELL FUNCTION; CELL REGENERATION; CELL SURVIVAL; CHRONIC INFLAMMATION; DRUG RESISTANCE; FIBROSIS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HOST PATHOGEN INTERACTION; HUMAN; HUMAN HERPESVIRUS 8; HUMAN T CELL LEUKEMIA VIRUS; IMMUNOCOMPETENT CELL; KAPOSI SARCOMA; KIDNEY TUBULE CELL; KNOCKOUT MOUSE; LISTERIA MONOCYTOGENES; LISTERIOSIS; LIVER CELL; LIVER CELL CARCINOMA; MALARIA; METASTASIS POTENTIAL; MORPHOGENESIS; NERVE CELL; NONHUMAN; PLASMODIUM; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN STRUCTURE; PROTO ONCOGENE; PSEUDOMONAS AERUGINOSA; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; STOMACH CARCINOGENESIS; T CELL LEUKEMIA; TISSUE SPECIFICITY; TUMOR INVASION; TUMOR MICROENVIRONMENT; URINARY TRACT INFECTION; UROPATHOGENIC ESCHERICHIA COLI; ANIMAL; BACTERIUM; DEFICIENCY; GENETICS; IMMUNOLOGY; INFECTION; METABOLISM; MOUSE; PATHOGENICITY; PHYSIOLOGY; VIRUS;

ANIMALS; BACTERIA; HEPATOCYTE GROWTH FACTOR; HEPATOCYTES; HUMANS; INFECTION; MICE; MICE, KNOCKOUT; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION; VIRUSES;

EID: 85009829105     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2016.12.025     Document Type: Review

References (117)

1. Nakamura, T., Nishizawa, T., Hagiya, M., Seki, T., Shimonishi, M., Sugimura, A., et al. Molecular cloning and expression of human hepatocyte growth factor. Nature 342 (1989), 440–443.
2. Miyazawa, K., Tsubouchi, H., Naka, D., Takahashi, K., Okigaki, M., Arakaki, N., et al. Molecular cloning and sequence analysis of cDNA for human hepatocyte growth factor. Biochem. Biophys. Res. Commun. 163 (1989), 967–973.
3. Stoker, M., Gherardi, E., Perryman, M., Gray, J., Scatter factor is a fibroblast derived modulator of epithelial cell mobility. Nature 327 (1987), 239–242.
4. Weidner, K.M., Behrens, J., van der Kerckhove, J., Birchmeier, W., Scatter factor: molecular characteristics and effect on the invasiveness of epithelial cells. J. Cell Biol. 111 (1990), 2097–2108.
5. Montesano, R., Matsumoto, K., Nakamura, T., Orci, L., Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor. Cell 67 (1991), 901–908.
6. Bottaro, D.P., Rubin, J.S., Faletto, D.L., Chan, A.M., Kmiecik, T.E., Vande Woude, G.F., et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251 (1991), 802–804.
7. Naldini, L., Vigna, E., Narsimhan, R.P., Gaudino, G., Zarnegar, R., Michalopoulos, G.K., et al. Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET. Oncogene 6 (1991), 501–504.
8. Cooper, C.S., Park, M., Blair, D.G., Tainsky, M.A., Huebner, K., Croce, C.M., et al. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 311 (1984), 29–33.
9. Park, M., Dean, M., Cooper, C.S., Schmidt, M., O'Brien, S.J., Blair, D.G., et al. Mechanism of met oncogene activation. Cell 45 (1986), 895–904.
10. Uehara, Y., Minowa, O., Mori, C., Shiota, K., Kuno, J., Noda, T., Kitamura, N., Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature 373 (1995), 702–705.
11. Bladt, F., Riethmacher, D., Isenmann, S., Aguzzi, A., Birchmeier, C., Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 376 (1995), 768–771.
12. Huh, C.G., Factor, V.M., Sanchez, A., Uchida, K., Conner, E.A., Thorgeirsson, S.S., Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc. Natl. Acad. Sci. USA 101 (2004), 4477–4482.
13. Borowiak, M., Garratt, A.N., Wustefeld, T., Strehle, M., Trautwein, C., Birchmeier, C., Met provides essential signals for liver regeneration. Proc. Natl. Acad. Sci. USA 101 (2004), 10608–10613.
14. Factor, V.M., Seo, D., Ishikawa, T., Kaposi-Novak, P., Marquardt, J.U., Andersen, J.B., Conner, E.A., Thorgeirsson, S.S., Loss of c-Met disrupts gene expression program required for G2/M progression during liver regeneration in mice. PLoS ONE, 5, 2010, e12739.
15. Giebeler, A., Boekschoten, M.V., Klein, C., Borowiak, M., Birchmeier, C., Gassler, N., et al. C-Met confers protection against chronic liver tissue damage and fibrosis progression after bile duct ligation in mice. Gastroenterology 137 (2009), 297–308.
16. Marquardt, J.U., Seo, D., Gómez-Quiroz, L.E., Uchida, K., Gillen, M.C., Kitade, M., et al. Loss of c-Met accelerates development of liver fibrosis in response to CCl4 exposure through deregulation of multiple molecular pathways. Biochim. Biophys. Acta 2012 (1822), 942–951.
17. Del Castillo, G., Factor, V.M., Fernández, M., Alvarez-Barrientos, A., Fabregat, I., Thorgeirsson, S.S., Sánchez, A., Deletion of the Met tyrosine kinase in liver progenitor oval cells increases sensitivity to apoptosis in vitro. Am. J. Pathol. 172 (2008), 1238–1247.
18. Ishikawa, T., Factor, V.M., Marquardt, J.U., Raggi, C., Seo, D., Kitade, M., Conner, E.A., Thorgeirsson, S.S., Hepatocyte growth factor/c-met signaling is required for stem-cell-mediated liver regeneration in mice. Hepatology 55 (2012), 1215–1226.
19. Zhou, D., Tan, R.J., Lin, L., Zhou, L., Liu, Y., Activation of hepatocyte growth factor receptor, c-met, in renal tubules is required for renoprotection after acute kidney injury. Kidney Int. 84 (2013), 509–520.
20. Dai, C., Saleem, M.A., Holzman, L.B., Mathieson, P., Liu, Y., Hepatocyte growth factor signaling ameliorates podocyte injury and proteinuria. Kidney Int. 77 (2010), 962–973.
21. Ma, H., Saenko, M., Opuko, A., Togawa, A., Soda, K., Marlier, A., Moeckel, G.W., Cantley, L.G., Ishibe, S., Deletion of the Met receptor in the collecting duct decreases renal repair following ureteral obstruction. Kidney Int. 76 (2009), 868–876.
22. Ishibe, S., Karihaloo, A., Ma, H., Zhang, J., Marlier, A., Mitobe, M., et al. Met and the epidermal growth factor receptor act cooperatively to regulate final nephron number and maintain collecting duct morphology. Development 136 (2009), 337–345.
23. Chmielowiec, J., Borowiak, M., Morkel, M., Stradal, T., Munz, B., Werner, S., et al. C-Met is essential for wound healing in the skin. J. Cell Biol. 177 (2007), 151–162.
24. Dai, C., Huh, C.G., Thorgeirsson, S.S., Liu, Y., β-Cell-specific ablation of the hepatocyte growth factor receptor results in reduced islet size, impaired insulin secretion, and glucose intolerance. Am. J. Pathol. 167 (2005), 429–436.
25. Roccisana, J., Reddy, V., Vasavada, R.C., Gonzalez-Pertusa, J.A., Magnuson, M.A., Garcia-Ocaña, A., Targeted inactivation of hepatocyte growth factor receptor c-met in β-cells leads to defective insulin secretion and GLUT-2 downregulation without alteration of β-cell mass. Diabetes 54 (2005), 2090–2102.
26. Mellado-Gil, J., Rosa, T.C., Demirci, C., Gonzalez-Pertusa, J.A., Velazquez-Garcia, S., Ernst, S., et al. Disruption of hepatocyte growth factor/c-Met signaling enhances pancreatic β-cell death and accelerates the onset of diabetes. Diabetes 60 (2011), 525–536.
27. Martins, G.J., Shahrokh, M., Powell, E.M., Genetic disruption of Met signaling impairs GABAergic striatal development and cognition. Neuroscience 176 (2011), 199–209.
28. Smith, J.M., Xu, J., Powell, E.M., Age dependent forebrain structural changes in mice deficient in the autism associated gene Met tyrosine kinase. Neuroimage Clin. 1 (2012), 66–74.
29. Judson, M.C., Eagleson, K.L., Wang, L., Levitt, P., Evidence of cell-nonautonomous changes in dendrite and dendritic spine morphology in the met-signaling-deficient mouse forebrain. J. Comp. Neurol. 518 (2010), 4463–4478.
30. Qiu, S., Anderson, C.T., Levitt, P., Shepherd, G.M., Circuit-specific intracortical hyperconnectivity in mice with deletion of the autism-associated Met receptor tyrosine kinase. J. Neurosci. 31 (2011), 5855–5864.
31. Arechederra, M., Carmona, R., González-Nuñez, M., Gutiérrez-Uzquiza, A., Bragado, P., Cruz-González, I., et al. Met signaling in cardiomyocytes is required for normal cardiac function in adult mice. Biochim. Biophys. Acta 2013 (1832), 2204–2215.
32. Baek, J.H., Birchmeier, C., Zenke, M., Hieronymus, T., The HGF receptor/Met tyrosine kinase is a key regulator of dendritic cell migration in skin immunity. J. Immunol. 189 (2012), 1699–1707.
33. Shen, Y., Naujokas, M., Park, M., Ireton, K., InIB-dependent internalization of Listeria is mediated by the Met receptor tyrosine kinase. Cell 103 (2000), 501–510.
34. Chen, C.K., Yang, C.Y., Hua, K.T., Ho, M.C., Johansson, G., Jeng, Y.M., et al. Leukocyte cell-derived chemotaxin 2 antagonizes MET receptor activation to suppress hepatocellular carcinoma vascular invasion by protein tyrosine phosphatase 1B recruitment. Hepatology 59 (2014), 974–985.
35. Tamagnone, L., Comoglio, P.M., Control of invasive growth by hepatocyte growth factor (HGF) and related scatter factors. Cytokine Growth Factor Rev. 8 (1997), 129–142.
36. Miyazawa, K., Shimomura, T., Kitamura, A., Kondo, J., Morimoto, Y., Kitamura, N., Molecular cloning and sequence analysis of the cDNA for a human serine protease responsible for activation of hepatocyte growth factor. Structural similarity of the protease precursor to blood coagulation factor XII. J. Biol. Chem. 268 (1993), 10024–10028.
37. Lee, S.L., Dickson, R.B., Lin, C.Y., Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J. Biol. Chem. 275 (2000), 36720–36725.
38. Herter, S., Piper, D.E., Aaron, W., Gabriele, T., Cutler, G., Cao, P., et al. Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers. Biochem. J. 390 (2005), 125–136.
39. Matsumoto, K., Nakamura, T., Emerging multipotent aspects of hepatocyte growth factor. J. Biochem. 119 (1996), 591–600.
40. Kataoka, H., Miyata, S., Uchinokura, S., Itoh, H., Roles of hepatocyte growth factor (HGF) activator and HGF activator inhibitor in the pericellular activation of HGF/scatter factor. Cancer Metastasis Rev. 22 (2003), 223–236.
41. Parr, C., Jiang, W.G., Hepatocyte growth factor activation inhibitors (HAI-1 and HAI-2) regulate HGF-induced invasion of human breast cancer cells. Int. J. Cancer 119 (2006), 1176–1183.
42. Kobayashi, T., Honke, K., Miyazaki, T., Matsumoto, K., Nakamura, T., Ishizuka, I., et al. Hepatocyte growth factor specifically binds to sulfoglycolipids. J. Biol. Chem. 269 (1994), 9817–9821.
43. Taipale, J., Keski-Oja, J., Growth factors in the extracellular matrix. FASEB J. 11 (1997), 51–59.
44. Lyon, M., Deakin, J.A., Rahmoune, H., Fernig, D.G., Nakamura, T., Hepatocyte growth factor/scatter factor binds with high affinity to dermatan sulfate. J. Biol. Chem. 273 (1998), 271–278.
45. Birchmeier, C., Gherardi, E., Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends Cell Biol. 8 (1998), 404–410.
46. Neuss, S., Beher, E., Wöltje, M., Tietze, L., Jahnen-Dechent, W., Functional expression of HGF and HGF receptor/c-met in adult human mesenchymal stem cells suggests a role in cell mobilization, tissue repair, and wound healing. Stem Cells 22 (2004), 405–414.
47. van de Kamp, J., Jahnen-Dechent, W., Rath, B., Knuechel, R., Neuss, S., Hepatocyte growth factor-loaded biomaterials for mesenchymal stem cell recruitment. Stem Cells Int., 2013, 10.1155/2013/892065.
48. Rahimi, N., Tremblay, E., McAdam, L., Park, M., Schwall, R., Elliott, B., Identification of a hepatocyte growth factor autocrine loop in a murine mammary carcinoma. Cell Growth Differ. 7 (1996), 263–270.
49. Nishida, S., Hirohashi, Y., Torigoe, T., Inoue, R., Kitamura, H., Tanaka, T., et al. Prostate cancer stem-like cells/cancer-initiating cells have an autocrine system of hepatocyte growth factor. Cancer Sci. 104 (2013), 431–436.
50. Xie, Q., Bradley, R., Kang, L., Koeman, J., Ascierto, M.L., Worschech, A., et al. Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma. Proc. Natl. Acad. Sci. USA 109 (2012), 570–575.
51. Yi, S., Tsao, M.S., Activation of hepatocyte growth factor-met autocrine loop enhances tumorigenicity in a human lung adenocarcinoma cell line. Neoplasia 2 (2000), 226–234.
52. Park, M., Dean, M., Kaul, K., Braun, M.J., Gonda, M.A., Vande, Woude G., Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors. Proc. Natl. Acad. Sci. USA 84 (1987), 6379–6383.
53. Gherardi, E., Sandin, S., Petoukhov, M.V., Finch, J., Youles, M.E., Ofverstedt, L.G., et al. Structural basis of hepatocyte growth factor/scatter factor and MET signaling. Proc. Natl. Acad. Sci. USA 103 (2006), 4046–4051.
54. Basilico, C., Arnesano, A., Galluzzo, M., Comoglio, P.M., Michieli, P.A., High affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met. J. Biol. Chem. 283 (2008), 21267–21277.
55. Weidner, K.M., di Cesare, S., Sachs, M., Brinkmann, V., Behrens, J., Birchmeier, W., Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis. Nature 384 (1996), 173–176.
56. Sachs, M., Brohmann, H., Zechner, D., Müller, T., Hülsken, J., Walther, I., et al. Essential role of Gab1 for signaling by the c-Met receptor in vivo. J. Cell Biol. 150 (2000), 1375–1384.
57. Liu, Y., Hepatocyte growth factor promotes renal epithelial cell survival by dual mechanisms. Am. J. Physiol. 277 (1999), F624–F633.
58. Garcia-Ocana, A., Takane, K.K., Reddy, V.T., Lopez-Talavera, J.C., Vasavada, R.C., Stewart, A.F., Adenovirus-mediated hepatocyte growth factor expression in mouse islets improves pancreatic islet transplant performance and reduces β-cell death. J. Biol. Chem. 278 (2003), 343–351.
59. Wang, X., DeFrances, M.C., Dai, Y., Pediaditakis, P., Johnson, C., Bell, A., et al. A mechanism of cell survival: Sequestration of Fas by the HGF receptor Met. Mol. Cell 9 (2002), 411–421.
60. Ma, J., Zou, C., Guo, L., Seneviratne, D.S., Tan, X., Kwon, Y.K., Novel death defying domain in Met entraps the active site of caspase-3 and blocks apoptosis in hepatocytes. Hepatology 59 (2014), 2011–2022.
61. Peschard, P., Fournier, T.M., Lamorte, L., Naujokas, M.A., Band, H., Langdon, W.Y., Park, M., Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol. Cell 8 (2001), 995–1004.
62. Gui, Y., Yeganeh, M., Donates, Y.C., Tobelaim, W.S., Chababi, W., Mayhue, M., et al. Regulation of MET receptor tyrosine kinase signaling by suppressor of cytokine signaling 1 in hepatocellular carcinoma. Oncogene 34 (2015), 5718–5728.
63. Hashigasako, A., Machide, M., Nakamura, T., Matsumoto, K., Nakamura, T., Bi-directional regulation of Ser-985 phosphorylation of c-met via protein kinase-C and protein phosphatase 2A involves c-Met activation and cellular responsiveness to hepatocyte growth factor. J. Biol. Chem. 279 (2004), 26445–26452.
64. Nakayama, M., Sakai, K., Yamashita, A., Nakamura, T., Suzuki, Y., Matsumoto, K., Met/HGF receptor activation is regulated by juxtamembrane Ser985 phosphorylation in hepatocytes. Cytokine 62 (2013), 446–452.
65. Wu, Y., Yao, X., Zhu, M., Qian, H., Jiang, L., Lan, T., et al. PKG II reverses HGF-triggered cellular activities by phosphorylating serine 985 of c-Met in gastric cancer cells. Oncotarget 7 (2016), 34190–34200.
66. Nakamura, T., Sakai, K., Nakamura, T., Matsumoto, K., Hepatocyte growth factor twenty years on: much more than a growth factor. J. Gastroenterol. Hepatol. 26 (2011), 188–202.
67. Knudsen, B.S., Vande, Woude G., Showering c-MET-dependent cancers with drugs. Curr. Opin. Genet. Dev. 18 (2008), 87–96.
68. Gherardi, E., Birchmeier, W., Birchmeier, C., Vande, Woude G., Targeting MET in cancer: rationale and progress. Nat. Rev. Cancer 12 (2012), 89–103.
69. Comoglio, P.M., Giordano, S., Trusolino, L., Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat. Rev. 7 (2008), 504–516.
70. Cecchi, F., Rabe, D.C., Bottaro, D.P., Targeting the HGF/Met signaling pathway in cancer therapy. Expert Opin. Ther. Targets 16 (2012), 553–572.
71. Sakai, K., Aoki, S., Matsumoto, K., Hepatocyte growth factor and Met in drug discovery. J. Biochem. 157 (2015), 271–284.
72. Ilangumaran, S., Villalobos-Hernandez, A., Bobbala, D., Ramanathan, S., The hepatocyte growth factor (HGF)–MET receptor tyrosine kinase signaling pathway: diverse roles in modulating immune cell functions. Cytokine 82 (2016), 125–139.
73. Carrolo, M., Giordano, S., Cabrita-Santos, L., Corso, S., Vigario, A.M., Silva, S., et al. Hepatocyte growth factor and its receptor are required for malaria infection. Nat. Med. 9 (2003), 1363–1369.
74. Leirião, P., Albuquerque, S.S., Corso, S., van Gemert, Geert-Jan, Sauerwein, R.W., Rodriguez, A., Giordano, S., Mota, M.M., HGF/MET signalling protects Plasmodium-infected host cells from apoptosis. Cellular Microbiol. 7 (2005), 603–609.
75. Sattabongkot, J., Yimamnuaychoke, N., Leelaudomlipi, S., Rasameesoraj, M., Jenwithisuk, R., Coleman, R., et al. Establishment of a human hepatocyte line that supports in vitro development of the exo-erythrocytic stages of the malaria parasites Plasmodium falciparum and P. vivax. Am. J. Trop. Med. Hyg. 74 (2006), 708–715.
76. Tao, D., King, J.G., Tweedell, R.E., Jost, P.J., Boddey, J.A., Dinglasan, R.R., The acute transcriptomic and proteomic response of HC-04 hepatoma cells to hepatocyte growth factor and its implications for Plasmodium falciparum sporozoite invasion. Mol. Cellular Proteomics 13 (2014), 1153–1164.
77. Suerbaum, S., Michetti, P., Helicobacter pylori infection. N. Engl. J. Med. 347 (2002), 1175–1186.
78. Vogelmann, R., Amieva, M.R., The role of bacterial pathogens in cancer. Curr. Opin. Microbiol. 10 (2007), 76–81.
79. Guillemin, K., Salama, N.R., Tompkins, T.S., Falkow, S., Cag pathogenicity island-specific responses of gastric epithelial cells to Helicobacter pylori infection. Proc. Natl. Acad. Sci. USA 99 (2002), 15136–15141.
80. Segal, E.D., Cha, J., Lo, J., Falkow, S., Tompkins, L.S., Altered states: involvement of phosphorylated CagA in the induction of host cellular growth changes by Helicobacter pylori. Proc. Natl. Acad. Sci. USA 96 (1999), 14559–14564.
81. Odenbreit, S., Puls, J., Sedlmaier, B., Gerland, E., Fischer, W., Haas, R., Translocation of Helicobacter pylori CagA into gastric epithelial cells by type IV secretion. Science 287 (2000), 1497–1500.
82. Backert, S., Meyer, T.F., Type IV secretion systems and their effectors in bacterial pathogenesis. Curr. Opin. Microbiol. 9 (2006), 207–217.
83. Churin, Y., Al-Ghoul, L., Kepp, O., Meyer, T.F., Birchmeier, W., Naumann, M., Helicobacter pylori CagA protein targets the c-Met receptor and enhances the motogenic response. J. Cell Biol. 134 (2003), 689–698.
84. Oliveira, M.J., Costa, A.C., Costa, A.M., Henriques, L., Suriano, G., Atherton, J.C., et al. Helicobacter pylori induces gastric epithelial cell invasion in a c-Met and Type IV secretion system-dependent manner. J. Biol. Chem. 281 (2006), 34888–34896.
85. Oliveira, M.J., Costa, A.M., Costa, A.C., Ferreira, R.M., Sampaio, P., Machado, J.C., et al. CagA associates with c-Met, E-cadherin, and p120-catenin in a multiprotein complex that suppresses Helicobacter pylori–induced cell-Invasive phenotype. J. Infect. Dis. 200 (2009), 745–755.
86. El-Etr, S.H., Mueller, A., Tompkins, L.S., Falkow, S., Merrell, D.S., Phosphorylation-independent effects of CagA during interaction between Helicobacter pylori and T84 polarized monolayers. J. Infect. Dis. 190 (2004), 1516–1523.
87. Hirata, Y., Maeda, S., Mitsuno, Y., Tateishi, K., Yanai, A., Akanuma, M., et al. Helicobacter pylori CagA protein activates serum response element-driven transcription independently of tyrosine phosphorylation. Gastroenterology 123 (2002), 1962–1971.
88. Suzuki, M., Mimuro, H., Kiga, K., Fukumatsu, M., Ishijima, N., Morikawa, H., et al. Helicobacter pylori CagA phosphorylation-independent function in epithelial proliferation and inflammation. Cell Host Microbe 5 (2009), 23–34.
89. Athauda, G., Giubellino, A., Coleman, J.A., Horak, C., Steeg, P.S., Lee, M.J., et al. C-Met ectodomain shedding rate correlates with malignant potential. Clin. Cancer Res. 12 (2006), 4154–4162.
90. Xu, K.P., Yu, F.S., Cross talk between c-Met and epidermal growth factor receptor during retinal pigment epithelial wound healing. Invest. Ophthalmol. Vis. Sci. 48 (2007), 2242–2248.
91. Schirrmeister, W., Gnad, T., Wex, T., Higashiyama, S., Wolke, C., Naumann, M., Lendeckel, U., Ectodomain shedding of E-cadherin and c-Met is induced by Helicobacter pylori infection. Exp. Cell. Res. 315 (2009), 3500–3508.
92. Franke, R., Müller, M., Wundrack, N., Gilles, E.D., Klamt, S., Kähne, T., Naumann, M., Host-pathogen systems biology: logical modelling of hepatocyte growth factor and Helicobacter pylori induced c-Met signal transduction. BMC Syst. Biol., 2, 2008, 4, 10.1186/1752-0509-2-4.
93. McCracken, K.W., Cata, E.M., Crawford, C.M., Sinagoga, K.L., Schumacher, M., Rockich, B.E., et al. Modelling human development and disease in pluripotent stem-cell-derived gastric organoids. Nature 516 (2014), 400–404.
94. Nakamura, M., Takahashi, T., Matsui, H., Baniwa, Y., Takahashi, S., Murayama, S.Y., et al. Alteration of angiogenesis in Helicobacter heilmannii-induced mucosa-associated lymphoid tissue lymphoma: interaction with c-Met and hepatocyte growth factor. J. Gastroenterol. Hepatol. 29 (2014), 70–76.
95. Swaminathan, B., Gerner-Smidt, P., The epidemiology of human listeriosis. Microbes Infect. 9 (2007), 1236–1243.
96. Lecuit, M., Human listeriosis and animal models. Microbes Infect 9 (2007), 1216–1225.
97. Disson, O., Lecuit, M., In vitro and in vivo models to study human listeriosis: mind the gap. Microbes Infect. 15 (2013), 971–980.
98. Jiwani, S., Wang, Y., Dowd, G.C., Gianfelice, A., Pichestapong, P., Gavicherla, B., et al. Identification of components of the host type IA phosphoinositide 3-kinase pathway that promote internalization of Listeria monocytogenes. Infect. Immun. 80 (2012), 1252–1266.
99. Gessain, G., Tsai, Y., Travier, L., Bonazzi, M., Grayo, S., Cossart, P., et al. PI3-kinase activation is critical for host barrier permissiveness to Listeria monocytogenes. J. Exp. Med. 212 (2015), 165–183.
100. Niemann, H.H., Jäger, V., Butler, P.J.G., van den Heuvel, J., Schmidt, S., Ferraris, D., et al. Structure of the human receptor tyrosine kinase Met in complex with the Listeria invasion protein InlB. Cell 130 (2007), 235–246.
101. Hamon, M., Bierne, H., Cossart, P., Listeria monocytogenes: a multifaceted model. Nat. Rev. Microbiol. 4 (2006), 423–434.
102. Mungunsukh, O., Lee, Y.H., Marquez, A.P., Cecchi, F., Bottaro, D.P., Day, R.M., A tandem repeat of a fragment of Listeria monocytogenes internalin B protein induces cell survival and proliferation. Am. J. Physiol. Lung Cell Mol. Physiol. 299 (2010), L905–L914.
103. Kolditz, F., Krausze, J., Heinz, D.W., Niemann, H.H., Müller-Goymann, C.C., Wound healing potential of a dimeric InlB variant analyzed by in vitro experiments on re-epithelialization of human skin models. Eur. J. Pharma. Biopharma. 86 (2014), 277–283.
104. Wu, J.H., Billings, B.J., Balkovetz, D.F., Hepatocyte growth factor alters renal epithelial cell susceptibility to uropathogenic Escherichia coli. J. Am. Soc. Nephrol. 12 (2001), 2543–2553.
105. Jiang, X., McClellan, S.A., Barrett, R., Foldenauer, M., Hazlett, L.D., HGF signaling impacts severity of Pseudomonas aeruginosa keratitis. Invest. Ophthalmol. Vis. Sci. 55 (2014), 2180–2190.
106. Bhutani, M., Polizzotto, M.N., Uldrick, T.S., Yarchoan, R., Kaposi sarcoma-associated herpesvirus-associated malignancies: epidemiology, pathogenesis, and advances in treatment. Semin. Oncol. 42 (2015), 223–246.
107. Yanik, E.L., Napravnik, S., Cole, S.R., Achenbach, C.J., Gopal, S., Olshan, A., et al. Incidence and timing of cancer in HIV-infected individuals following initiation of combination antiretroviral therapy. Clin. Infect. Dis. 57 (2013), 756–764.
108. Tedeschi, R., Bidoli, E., Bortolin, M.T., Schioppa, O., Vaccher, E., De Paoli, P., Plasma biomarkers of clinical response during chemotherapy plus combination antiretroviral therapy (cART) in HIV+ patients with advanced Kaposi sarcoma. Oncotarget 6 (2015), 3034–30342.
109. Dai, L., Trillo-Tinoco, J., Cao, Y., Bonstaff, K., Doyle, L., Del Valle, L., et al. Targeting HGF/c-MET induces cell cycle arrest, DNA damage, and apoptosis for primary effusion lymphoma. Blood 126 (2015), 2821–2831.
110. Choi, Y.L., Tsukasaki, K., O'Neill, M.C., Yamada, Y., Onimaru, Y., Matsumoto, K., et al. A genomic analysis of adult T-cell leukemia. Oncogene 26 (2007), 1245–1255.
111. Wang, R., Ferrell, L.D., Faouzi, S., Maher, J.J., Bishop, J.M., Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J. Cell Biol. 153 (2001), 1023–1034.
112. Tward, A.D., Jones, K.D., Yant, S., Cheung, S.T., Fan, S.T., Chen, X., et al. Distinct pathways of genomic progression to benign and malignant tumors of the liver. Proc. Natl. Acad. Sci. USA 104 (2007), 14771–14776.
113. Ozden, M., Kalkan, A., Demirdag, K., Denk, A., Kilic, S.S., Hepatocyte growth factor (HGF) in patients with hepatitis B and meningitis. J. Infection 49 (2004), 229–235.
114. Barreiros, A.P., Sprinzl, M., Rosset, S., Höhler, T., Otto, G., Theobald, M., et al. EGF and HGF levels are increased during active HBV infection and enhance survival signaling through extracellular matrix interactions in primary human hepatocytes. Int. J. Cancer 124 (2009), 120–129.
115. Xie, Q., Su, Y., Dykema, K., Johnson, J., Koeman, J., De Giorgi, V., et al. Overexpression of HGF Promotes HBV-induced hepatocellular carcinoma progression and is an effective indicator for Met-targeting therapy. Genes Cancer 4 (2013), 247–260.
116. Zhu, B., Wei, X., Wang, T., Zho, Y., Liu, A., Zhang, G., Increased miR-16 expression induced by hepatitis C virus infection promotes liver fibrosis through downregulation of hepatocyte growth factor and Smad7. Arch. Virol. 160 (2015), 2043–2050.
117. Ito, K., Sakai, K., Suzuki, Y., Ozawa, N., Hatta, T., Natsume, T., Matsumoto, K., Suga, H., Artificial human Met agonists based on macrocycle scaffolds. Nat. Commun., 6, 2015, 6373.